drugset / Trial / NCT07225829

A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

NCT07225829

Phase 2 Recruiting 129 enrolled 4Moving Biotech
RandomizedParallel-groupDouble-blindTreatment

Summary

This phase 2a trial is an international, multicenter, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of one single intra-articular (IA) injection of 4P004 or placebo in: * patients between 40 and 80 years of age, * with synovitis and grade 2 to 4 osteoarthritis (OA) of the knee according to Kellgren and Lawrence (KL) classification.

Timeline

Start
2025-06-17
Primary completion
2026-07
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 2 ml Other